Munar Pharma (MUN) Stock Overview
Does not have significant operations. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MUN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Munar Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.33 |
| 52 Week High | zł0.54 |
| 52 Week Low | zł0.27 |
| Beta | 0.34 |
| 1 Month Change | 8.97% |
| 3 Month Change | -12.53% |
| 1 Year Change | -22.27% |
| 3 Year Change | -60.29% |
| 5 Year Change | -80.48% |
| Change since IPO | -90.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| MUN | PL Entertainment | PL Market | |
|---|---|---|---|
| 7D | 8.6% | 2.4% | -0.6% |
| 1Y | -22.3% | -6.7% | 25.2% |
Return vs Industry: MUN underperformed the Polish Entertainment industry which returned -6.7% over the past year.
Return vs Market: MUN underperformed the Polish Market which returned 25.2% over the past year.
Price Volatility
| MUN volatility | |
|---|---|
| MUN Average Weekly Movement | 7.3% |
| Entertainment Industry Average Movement | 4.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in PL Market | 10.3% |
| 10% least volatile stocks in PL Market | 3.0% |
Stable Share Price: MUN's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: MUN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 4 | Grzegorz Konrad | munar.pl |
Munar Pharma S.A. does not have significant operations. It previously engaged in the publishing of games. The company was formerly known as Munar S.A. and changed its name to Munar Pharma S.A. in June 2025.
Munar Pharma S.A. Fundamentals Summary
| MUN fundamental statistics | |
|---|---|
| Market cap | zł14.14m |
| Earnings (TTM) | -zł735.16k |
| Revenue (TTM) | zł250.00k |
Is MUN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MUN income statement (TTM) | |
|---|---|
| Revenue | zł250.00k |
| Cost of Revenue | zł251.38k |
| Gross Profit | -zł1.38k |
| Other Expenses | zł733.78k |
| Earnings | -zł735.16k |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.016 |
| Gross Margin | -0.55% |
| Net Profit Margin | -294.07% |
| Debt/Equity Ratio | 1.1% |
How did MUN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/29 17:08 |
| End of Day Share Price | 2026/07/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Munar Pharma S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.